// Area 02 — Therapeutics & Drug Development

A molecule that
survives the route.

Protein and biologic therapeutics — engineering for stability, expression and manufacturability, so a molecule that works at the bench survives the route to a clinical batch.

Modality
Proteins & biologics
We engineer
Stability, expression, developability
Constraint
Manufacturability from day one
Partners
CROs & contract manufacturers

// Therapeutics & drug development

Developability is a design input.

Treating manufacture as a later problem is what kills good molecules.

An alpha-helical protein backbone

A biologic that works in a flask and cannot be expressed at scale, or aggregates on storage, or loses activity through a purification train, is not a candidate. It is a result.

Developability constraints belong in the design, not in a review afterwards. We engineer for them from the start: expression host and construct strategy, thermal and colloidal stability, aggregation propensity, and the behaviour of the molecule through the steps it will actually go through.

Where we come in

  • Sequence and structure-level engineering for stability and expression.
  • Developability assessment in silico before committing laboratory time.
  • Construct design — formats, linkers, tags and the variants worth testing.
  • Aggregation and formulation behaviour under realistic conditions.
  • Working with the CROs and manufacturers who take the molecule forward.

Why in silico first

Because the expensive part is making and testing. Ranking candidates for affinity, stability, expression and developability before synthesis means the bench work starts from a shortlist that is already plausible, and each design–build–test cycle starts better informed than the last.

From discovery to a fundable case

The same engineering work decides whether a programme can be funded. There is a stage where a programme has a real biological result and no clear path to the next round: the science is not the problem, the evidence package is. Reviewers want target engagement shown cleanly, a candidate that can actually be made, and a route to a regulated product that someone has thought about.

  • Target engagement — designing the constructs and assays that show it convincingly.
  • Protein and construct engineering for the candidate and its controls.
  • In-silico triage so laboratory effort goes to the candidates worth making.
  • Preclinical groundwork: the experiments a diligence process will ask for.
  • An honest read on the IP position and the regulatory route.

What we assess before investing

The data as it stands, the intellectual property position, and whether a credible route to a regulated product exists. We would rather say no early and clearly than carry a programme that cannot get through the next gate.

// Capability

What we
actually do.

The specific pieces of work an engagement in this area is made of.

  • 01

    Developability triage

    In-silico assessment of stability, aggregation and expression risk before synthesis.

  • 02

    Stability engineering

    Sequence and structural changes that hold activity through storage and handling.

  • 03

    Expression strategy

    Host, construct and format decisions that make a useful yield achievable.

  • 04

    Format & construct design

    Linkers, fusions, tags and the variant set worth putting through the bench.

  • 05

    Manufacturability review

    Checking the molecule against the process it will actually be made by.

  • 06

    Partner handover

    Working alongside CROs and contract manufacturers who take it to a clinical batch.

// Questions

Asked
often.

If yours is not here, ask it directly — every enquiry is read by someone who can answer it.

  • Our molecule aggregates. Can that be engineered out?

    Often, yes — aggregation usually traces to identifiable surface patches or a stability deficit. Whether it can be fixed without losing activity is the real question, and it is answerable computationally before you spend on synthesis.

  • Do you manufacture?

    No. We design and engineer, and we work with the CROs and contract manufacturers who produce. Part of our support programme is sourcing and managing those relationships.

  • Can you improve expression without changing the binding site?

    That is usually the brief. Most of the levers for expression and stability sit away from the functional surface.

  • How early is too early?

    Rarely too early. If there is a target and a reason to believe, there is something to talk about. What we cannot help with is a programme that has no experimental result at all.

  • Do you take a position, or is this a service?

    Both are possible. Some engagements are investment against milestones; some are design and construct work paid for directly. We will say which one fits after reading the science.

  • What happens if you decline?

    We tell you why. If it is a stage problem rather than a science problem we will say what would change our answer.